The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
A step forward to implement leukemic stem cell assessment in the diagnostic workup of AML
Leukemic stem cells (LSCs) have been strongly associated with residual disease and relapse in patients with acute myeloid leukemia (AML). A higher frequency of...
May 28, 2020
FDA clears FT538, the first CRISPR-edited, iPSC-derived cell therapy, for investigation as a new drug in AML and MM
On May 20, 2020, the U.S. Food & Drug Administration (FDA) cleared FT538, the first CRISPR-edited, induced pluripotent stem cell...
May 26, 2020
Pretransplant FLT3/ITD status as a prognostic marker for outcome in FLT3-mutated AML
Internal tandem duplication (ITD) of the juxtamembrane domain of the FMS-like tyrosine kinase-3 (FLT3/ITD) gene is a common mutation detected in 30% of patients with...
May 25, 2020
Gert Ossenkoppele
" The AML Hub disseminates the most up-to-date information on AML for academic researchers and treating clinicians worldwide, to help improve their understanding of the latest advances in terms of research, biology, and treatment options. "